--- title: "The Liquidity Bifurcation in Hong Kong: From Crypto Inverse Products to Micro-Cap Anomalies" type: "News" locale: "en" url: "https://longbridge.com/en/news/296602497.md" description: "The key to understanding the current Hong Kong market lies in its extreme liquidity distribution. From leveraged MicroStrategy inverse ETFs to plunging biotechs, these unclassified long-tail stocks exemplify the market's structural fragmentation and fundamental revaluation." datetime: "2026-08-21T10:13:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296602497.md) - [en](https://longbridge.com/en/news/296602497.md) - [zh-HK](https://longbridge.com/zh-HK/news/296602497.md) generator: "portal-rs" --- # The Liquidity Bifurcation in Hong Kong: From Crypto Inverse Products to Micro-Cap Anomalies The key to understanding the current long-tail ecosystem of the Hong Kong stock market is understanding the restructuring of its underlying liquidity model. We are witnessing a classic "folded market": on one end, highly financialized, leveraged derivative instruments capture macro narrative volatility with precision; on the other, traditional industrial and biotech companies endure extreme valuation divergence and stress tests of their business models in a liquidity vacuum. When you examine these seemingly unrelated assets through the same value chain framework, it becomes clear they all serve as footnotes to Hong Kong's liquidity distribution mechanism. ### CSOP Bitcoin Futures Daily (-1x) Inverse Product (7376.HK) Since its launch in 2024, the significance of Asia's first Bitcoin futures inverse product extends far beyond a simple shorting tool. It is essentially a defensive aggregation by traditional exchanges competing for crypto asset pricing power. The product secured roughly USD 30 million in initial investment, and its net asset value has recently fluctuated alongside global risk assets. This means that investors no longer need to hold spot crypto or decentralized wallets to hedge macro risks—a textbook example of moving up the value chain. ### CSOP MicroStrategy Daily (-2x) Inverse Product (7399.HK) If 7376.HK represents a first-layer derivative, then 7399.HK is a derivative of a derivative. Because MicroStrategy itself is already treated by the market as a leveraged proxy for Bitcoin, offering a 2x inverse tracker of MicroStrategy pushes volatility to the absolute limit. This highly vertical instrument has seen active trading recently simply because the market demands a compliant, heavily leveraged pressure release valve amidst extreme decentralization manias. ### HighTide Therapeutics - B (2617.HK) Returning to real-world businesses, the manifestation of liquidity depletion looks vastly different, with HighTide Therapeutics serving as a prime case study. The company recently hit a major milestone in 2026 with the NMPA approval of its core product, Tinengotinib, marking year one of its commercialization. Yet, its market performance borders on the absurd: after joining the Stock Connect, its minimal free float caused shares to skyrocket over 50x before plunging in a single day. When an unprofitable biotech—which recorded a net loss of RMB 274 million in 2024 and still generates zero recurring revenue—encounters a concentrated burst of Southbound capital, fundamental valuation anchors completely fail. This is not a failure of fundamental analysis, but a direct reflection of structural market flaws. ### Sirnaomics (2257.HK) Sirnaomics presents another cautionary tale of biotech pivoting. Once the premier RNA stock, the company recorded zero revenue in 2025 and received a qualified audit opinion due to a massive, dubious investment write-off. In August 2026, the company even sued its founder to recover USD 20 million in investment losses. Facing this predicament, the firm is attempting to pivot into the medical aesthetics and fat-loss sector. This, though, is exactly backwards: when the underlying corporate governance and cash flows fracture, shifting product lines cannot re-aggregate investor confidence, as evidenced by its sustained underperformance this year. ### Universal Health International (2211.HK) In the traditional pharmaceutical distribution and retail space, Aggregation Theory applies equally. Universal Health International has attempted to build an "Internet + Health" platform, but in an era dominated by tech giants, platforms lacking traffic bottlenecks are quickly marginalized. Exchange data from August 2026 shows frequent multi-million-dollar position shifts and warehouse transfers, coupled with a proposed capital reorganization and share subdivision. These are typically desperate capital operations aimed at maintaining listing status in the absence of liquidity, aligning with its recent weak price action. ### TravelSky Technology (0696.HK) In the search for a true aggregator, TravelSky provides a textbook example. As the dominant IT solutions provider for China's aviation and travel industry, it does not operate flights, yet nearly all airlines and travel agencies must rely on its GDS system. A platform empowers third parties; an aggregator intermediates them. Through this irreplaceable infrastructure status, TravelSky commands immense pricing power and stable cash flows—a commercial moat that the vast majority of small-cap stocks cannot hope to replicate. ### Datang International Power Generation (0991.HK) The logic behind Datang Power reverts to the most fundamental laws of commodity supply and demand. As a traditional comprehensive power giant, the company successfully turned around in 2023, achieving a profit of RMB 1.439 billion. This was not the result of disruptive innovation, but purely the margin expansion brought by falling upstream coal prices. However, against the backdrop of long-term electricity demand driven by AI computing infrastructure, assets like this—despite lacking a sexy internet narrative—are undergoing a long-term revaluation as foundational energy suppliers. ### ISDN Holdings (1656.HK) Also benefiting from industrial upgrades and infrastructure expansion is ISDN Holdings. In Q1 2026, the company reported revenues of SGD 114 million, with after-tax profits surging an impressive 767% year-over-year. Deeply entrenched in motion control and industrial automation, the firm is perfectly positioned to capture the macro dividends of global manufacturing reshoring and production line automation. It proves that in specific niches, deep industry know-how and a global footprint provide far better downside protection than chasing the latest hype. ### China Merchants China Direct Investments (0133.HK) Finally, this PE fund illustrates an alternative way to cross the cycle. The highlight of its recent operations was the successful IPO of its portfolio company Insta360, which delivered massive single-day gains in 2025. Furthermore, a reported profitable exit from its UnionPay holdings has further padded its net asset value. This demonstrates that in today's fragmented secondary market, moving up the value chain by capturing top-tier assets in the private market and monetizing them via public markets remains an effective strategy. Ultimately, this seemingly random assortment of stocks forms a complete picture of the folded Hong Kong market: on the left, extreme financial leverage; on the right, physical enterprises enduring the cycle. The key to understanding the future of this market is not predicting short-term price levels, but seeing how capital flows and settles across these different dimensions of the value chain. *This article does not constitute investment advice.* ### Related Stocks - [02617.HK](https://longbridge.com/en/quote/02617.HK.md) - [01656.HK](https://longbridge.com/en/quote/01656.HK.md) - [02211.HK](https://longbridge.com/en/quote/02211.HK.md) - [02257.HK](https://longbridge.com/en/quote/02257.HK.md) ## Related News & Research - [Universal Health International Group Holding announces extraordinary general meeting](https://longbridge.com/en/news/297203817.md) - [Sirnaomics unit RNAimmune Vaccine signs shareholder agreement with Guangzhou Guangjian fund for RMB 30 million investment](https://longbridge.com/en/news/297033077.md) - [Transthera Sciences’ tinengotinib wins conditional China NMPA approval for cholangiocarcinoma](https://longbridge.com/en/news/297026275.md) - [TRANSTHERA-B Opens ~15% Higher as Proprietary New Drug 'Yochanra' Approved for Market Launch](https://longbridge.com/en/news/295169276.md) - [TransThera Completes Global Phase III Enrollment for Tinengotinib in Advanced Cholangiocarcinoma](https://longbridge.com/en/news/291409235.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**